/ /

Lynda Charters
Retinal prosthesis system ranks high in safety, performance
The Argus II Retinal Prosthesis System (Second Sight Medical Products) is providing a safe option for restoration of some visual function in patients with severe vision loss associated with retinitis pigmentosa.
New telemonitoring device makes impact in detecting CNV
Home monitoring of patients with age-related macular degeneration results in earlier detection of choroidal neovascularization with the ForeseeHome device resulted and increased preservation of vision.
Why patience is key for suprachoroidal hemorrhages and detachments
Surgery might not be the go-to option for suprachoroidal hemorrhages and detachments–they may resolve on their own. But when needed, a less invasive procedure can produce a quality outcome.
Bimatoprost sustained-release implants: Potential new pathway for glaucoma patients
The bimatoprost sustained-release implant (bimatoprost SR, Allergan) improves compliance for patients with problematic compliance with topical IOP-lowering glaucoma drugs and controlled the IOP for 6 months after injection.
SD-OCT: Enhanced visualization earlier in disease process
Spectral-domain optical coherence tomography facilitates detailed evaluation of foveal disorders even in the very earliest disease stages.
Wide-field imaging: ‘Big picture’ for quick, accurate diagnosis
Wide-field imaging has become an integral tool in the diagnosis and management of patients with retinal disease.
LHON therapy: Excellent safety and potential visual benefits
The intravitreal injection of a recombinant AAV2/2 vector with the wild-type ND4 gene might provide a safe and effective avenue to treat patients with Leber’s hereditary optic neuropathy.
Perfecting art of cataract surgery with guidance technologies
Cataract surgery technology continues to advance with improvements that enhance surgical performance every step of the way.
LASIK rivals contact lenses in visual acuity and comfort
Compared with daily wear contact lens wear, wavefront-guided LASIK results in better binocular uncorrected visual acuity and comparable subjective outcomes.
Sonepcizumab combination therapy may offer long-term visual acuity stabilization
Sonepcizumab alone or in combination with anti-VEGF does not provide any short-term benefit to the visual acuity in patients with wet AMD, who were considered to be subresponders to anti-VEGF therapy. However, a combination of therapies may have different results.


View Results